Amgen Stock Sees Opportunity Amidst Novartis-Driven Selloff
The stock price of Amgen (NASDAQ:AMGN) has seen a decline following the news that Novartis, one of its largest partners, is facing regulatory scrutiny. However, analysts at Seeking Alpha believe this presents an opportunity for investors to buy into the company.
A recent rating upgrade from a prominent analyst has led to increased confidence in Amgen's prospects. This upgrade suggests that despite the current selloff, the company's fundamentals remain strong and its partnership with Novartis will ultimately benefit its stock price.
The analyst notes that while Novartis's regulatory issues may cause short-term volatility, they are unlikely to have a lasting impact on Amgen's business. In fact, the partnership between the two companies is expected to drive growth for both parties in the long term.